Cytochrome P450 2C9 Inhibitors [MoA]: Side Effects & Safety Data for 16 Drugs
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
Cytochrome P450 2C9 Inhibitors [MoA] includes 16 drugs with a combined 114,235 adverse event reports in the FDA FAERS database. Compare their safety profiles, side effects, and outcomes below.
16
Drugs in Class
114,235
Combined Reports
All Cytochrome P450 2C9 Inhibitors [MoA] Drugs Ranked by Reports
| Drug | Brand Name | Reports | Deaths | Hosp. | Death Rate |
|---|---|---|---|---|---|
| AMIODARONE | Amiodarone Hydrochloride | 25,143 | 3,845 | 13,711 | 15.3% |
| CANNABIDIOL | Epidiolex | 18,243 | 1,563 | 5,149 | 8.6% |
| FLUCONAZOLE | Fluconazole | 15,157 | 2,546 | 5,821 | 16.8% |
| VORICONAZOLE | Voriconazole | 14,384 | 3,940 | 5,118 | 27.4% |
| AVAPRITINIB | Ayvakit | 10,117 | 302 | 942 | 3.0% |
| REGORAFENIB | Stivarga | 9,441 | 1,869 | 3,363 | 19.8% |
| EFAVIRENZ | Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate | 7,893 | 962 | 1,528 | 12.2% |
| IVACAFTOR | Kalydeco | 6,735 | 291 | 3,756 | 4.3% |
| CERITINIB | ZYKADIA | 2,796 | 786 | 804 | 28.1% |
| ETRAVIRINE | Intelence | 1,969 | 257 | 405 | 13.1% |
| ORITAVANCIN | Orbactiv | 884 | 29 | 157 | 3.3% |
| NITISINONE | Nitisinone | 752 | 96 | 198 | 12.8% |
| ORITAVANCIN DIPHOSPHATE | Kimyrsa | 276 | 4 | 27 | 1.4% |
| ACORAMIDIS | Attruby | 234 | 8 | 40 | 3.4% |
| ZAFIRLUKAST | ACCOLATE | 169 | 1 | 41 | 0.6% |
| TRICLABENDAZOLE | EGATEN | 42 | 0 | 4 | N/A |
Common Side Effects in Cytochrome P450 2C9 Inhibitors [MoA] Drugs
| Side Effect | Reports | Deaths |
|---|---|---|
| Drug ineffective | 9,571 | 2,867 |
| Off label use | 9,549 | 1,779 |
| Fatigue | 6,065 | 650 |
| Seizure | 5,374 | 138 |
| Diarrhoea | 5,363 | 549 |
| Drug interaction | 4,939 | 504 |
| Nausea | 4,607 | 623 |
| Death | 4,529 | 4,514 |
| Dyspnoea | 4,051 | 791 |
| Product use in unapproved indication | 3,666 | 570 |